Chemistry:VGX-1027
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C11H11NO3 |
| Molar mass | 205.213 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
VGX-1027 (GIT-27) is a drug which acts as an immunomodulator. It acts by blocking downstream signalling of the Toll-like receptors TLR2, TLR4 and TLR6, and thereby reducing production of various cytokines, including interleukins and TNF-α. In animal studies it has antiinflammatory effects and has been investigated for conditions such as arthritis and lung inflammation.[1][2][3][4][5][6]
References
- ↑ "In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models". Clinical Immunology 123 (3): 311–23. June 2007. doi:10.1016/j.clim.2007.03.004. PMID 17449326.
- ↑ "Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice". Endocrinology 154 (6): 2144–55. June 2013. doi:10.1210/en.2012-2080. PMID 23568555.
- ↑ "Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway". Cell Death & Disease 6 (5): e1752. May 2015. doi:10.1038/cddis.2015.125. PMID 25950482.
- ↑ "Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects". Clinical Pharmacology in Drug Development 5 (2): 91–101. March 2016. doi:10.1002/cpdd.193. PMID 27138022.
- ↑ "Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness". European Journal of Pharmacology 842: 373–383. January 2019. doi:10.1016/j.ejphar.2018.11.010. PMID 30419239.
- ↑ "The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4+ T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T+ Itpr3tf/J mice". Life Sciences 237: 116930. November 2019. doi:10.1016/j.lfs.2019.116930. PMID 31610190.
 |  |
